Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the ...

Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...

Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...

Eli Lilly and Company’s LLY stock crossed the $1000 per share mark for the first time on Nov. 12, reaching new highs. It is ...

Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market. Click here to read my latest ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of ABL Bio, after it struck a $2.6 billion licensing and joint ...

Lilly's tirzepatide is sold as Mounjaro for Type 2 diabetes and as Zepbound for weight loss -- but doctors have prescribed ...

David Ricks' remarks followed a recent White House event where Trump announced his administration had reached a deal to lower ...

Hidden homeowner costs climb to nearly $16,000 a year, Eli Lilly approaches trillion-dollar status amid weight-loss drug ...

Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.

Eli Lilly and Co.’s stock hit an all-time high and almost reached $1,000 per share on Tuesday in the wake of several ...

The Michigan Supreme Court heard oral arguments Wednesday in the state attorney general’s case against insulin-maker Eli ...